Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26004385 | 0.79 | MLYCD (0.39) | MLYCDEPHX2GAAMEN1KMT2A | |
| SCHEMBL1709282 | 0.74 | MEN1 (0.48) | MLYCDEPHX2GAAMEN1KMT2A | |
| SCHEMBL8645031 | 0.73 | KDM4E (0.43) | MLYCDEPHX2GAAMEN1KMT2A | |
| SCHEMBL29291003 | 0.73 | EPHX2 (0.42) | MLYCDEPHX2GAAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7451357 | 0.72 | MLYCD (0.41) | MLYCDEPHX2GAAMEN1KMT2A | |
| SCHEMBL13991916 | 0.71 | MLYCD (0.39) | MLYCDEPHX2GAAMEN1KMT2A | |
| SCHEMBL4960461 | 0.71 | MLYCD (0.40) | MLYCDEPHX2GAAMEN1KMT2A | |
| SCHEMBL2799440 | 0.70 | TDP1 (0.56) | MLYCDEPHX2GAAMEN1KMT2A | |
| SCHEMBL18914456 | 0.70 | EPHX2 (0.42) | MLYCDEPHX2GAAMEN1KMT2A | |
| SCHEMBL947583 | 0.69 | CASP2 (0.48) | MLYCDEPHX2GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | RORA, RORC, RORB | MLYCD 3140/4885EPHX2 266/4885GAA 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.